Peel Therapeutics Closes $9M Financing Round
- Peel Therapeutics, a Salt Lake City, UT-based clinical-stage biotech company, secured $9M in funding, bringing its total seed financing to $36M
- The company intends to use the funds to advance clinical and pre-clinical programs
- PeelTherapeutics is a clinical-stage biotech company that is advancing a therapeutic pipeline to treat a spectrum of devastating conditions, with a near-term focus on cancer and inflammation
- The company has raised a total of $36M in seed financing, plus over $3M in non-dilutive capital
- Peel also expanded its Board of Directors to support and guide the company through this rapid growth stage
- The new additions include Ryan Watts, CEO, Denali Therapeutics and Carin Canale-Theakston, CEO, Evoke Canale
